Molecular targets of luteolin in cancer

被引:139
作者
Tuorkey, Muobarak J. [1 ]
机构
[1] Damanhour Univ, Dept Zool, Fac Sci, Div Physiol, Damanhour 22111, Al Behira, Egypt
关键词
cell cycle arrest; DNA methylation; histone modification; PI3K; Akt; mTOR pathway; Wnt; -catenin signaling; EPITHELIAL-MESENCHYMAL TRANSITION; CELL-CELL CONTACT; ENDOPLASMIC-RETICULUM STRESS; LUNG-CARCINOMA CELLS; FATTY-ACID SYNTHASE; HUMAN TUMOR-CELLS; KAPPA-B PATHWAY; INDUCED APOPTOSIS; DOWN-REGULATION; GROWTH-FACTOR;
D O I
10.1097/CEJ.0000000000000128
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Many food-derived phytochemical compounds and their derivatives represent a cornucopia of new anticancer compounds. Despite extensive study of luteolin, the literature has no information on the exact mechanisms or molecular targets through which it deters cancer progression. This review discusses existing data on luteolin's anticancer activities and then offers possible explanations for and molecular targets of its cancer-preventive action. Luteolin prevents tumor development largely by inactivating several signals and transcription pathways essential for cancer cells. This review also offers insights into the molecular mechanisms and targets through which luteolin either prevents cancer or mediates cancer cell death.
引用
收藏
页码:65 / 76
页数:12
相关论文
共 128 条
[31]   Cathepsin L Proteolytically Processes Histone H3 During Mouse Embryonic Stem Cell Differentiation [J].
Duncan, Elizabeth M. ;
Muratore-Schroeder, Tara L. ;
Cook, Richard G. ;
Garcia, Benjamin A. ;
Shabanowitz, Jeffrey ;
Hunt, Donald F. ;
Allis, C. David .
CELL, 2008, 135 (02) :284-294
[32]   Cancer Associated Fibroblasts express pro-inflammatory factors in human breast and ovarian tumors [J].
Erez, Neta ;
Glanz, Sarah ;
Raz, Yael ;
Avivi, Camilla ;
Barshack, Iris .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2013, 437 (03) :397-402
[33]   Current development of mTOR inhibitors as anticancer agents [J].
Faivre, Sandrine ;
Kroemer, Guido ;
Raymond, Eric .
NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (08) :671-688
[34]   Luteolin inhibits insulin-like growth factor 1 receptor signaling in prostate cancer cells [J].
Fang, Jing ;
Zhou, Qiong ;
Shi, Xiang-lin ;
Jiang, Bing-hua .
CARCINOGENESIS, 2007, 28 (03) :713-723
[35]  
Farkas SA, 2014, EPIGENOMICS-UK, V6, P179, DOI [10.2217/EPI.14.7, 10.2217/epi.14.7]
[36]  
Fu J., 2012, PLOS ONE, V7
[37]   Hypomethylating Agents and Other Novel Strategies in Myelodysplastic Syndromes [J].
Garcia-Manero, Guillermo ;
Fenaux, Pierre .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (05) :516-523
[38]   An autophagic switch in the response of tumor cells to radiation and chemotherapy [J].
Gewirtz, David A. .
BIOCHEMICAL PHARMACOLOGY, 2014, 90 (03) :208-211
[39]   HGF/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development [J].
Hack, Stephen P. ;
Bruey, Jean-Marie ;
Koeppen, Hartmut .
ONCOTARGET, 2014, 5 (10) :2866-2880
[40]   Luteolin induces intrinsic apoptosis via inhibition of E6/E7 oncogenes and activation of extrinsic and intrinsic signaling pathways in HPV-18-associated cells [J].
Ham, Sunyoung ;
Kim, Ki Hong ;
Kwon, Tae Ho ;
Bak, Yesol ;
Lee, Dong Hun ;
Song, Yong Seok ;
Park, Su-Ho ;
Park, Yun Sun ;
Kim, Man Sub ;
Kang, Jeong Woo ;
Hong, Jin Tae ;
Yoon, Do-Young .
ONCOLOGY REPORTS, 2014, 31 (06) :2683-2691